Search 

Based at St Georges University of London, Richmond Pharmacology Limited is one of 14 MHRA accredited UK phase one units specialising in early phase Adaptive Studies (including First-In-Human), Cardiac Safety/Intensive ECG/Thorough QT studies, Ethnic Bridging studies and Patient Studies.

Our Principal Investigators offer peer-to-peer advice, intelligent protocol design and development and expert know-how for global regulatory requirements.Our streamlined methods ensure we deliver each milestone right on cue, with no extensions and no extra cost.

Synpromics is a Synthetic Biology company with IP and know-how in the design of Synthetic Promoters.

Our synthetic promoters enable the controlled expression of genes at a specific place, in a specific environment, at a specific time, or in response to a specific biological condition.

We provide solutions to our customers across multiple fields of use. Such as biotherapeutic protein production; targeted gene therapies and DNA vaccines; enhanced functionality of cell therapies; as well as research tools.

Our clients use our promoters in their applications and products. As each promoter is IP protected it allows us to generate revenue through license agreements that provide up-front and milestone payments during our clients product development, and attractive royalties on our clients product sales.

Tecrea Ltd is a UK based Biotechnology Company focused on nanotechnology as a means of creating novel drug formulations to treat serious medical conditions in human and animal health. Our Nanocin™ nanotechnology platform has already been partnered in both human and animal health. Commercial traction has been achieved with sales and out-licensing to bioprocessing and pharmaceutical companies, with one of our partners entering phase II clinical development early in 2017.

Ubiquigent provides its partners with unparalleled access to the technologies, skills and expertise required to support drug discovery in the ubiquitin field. The ubiquitin system offers many new drug discovery target opportunities across multiple therapeutic areas including cancer, cardiovascular and metabolic, neurological and musculoskeletal, and infection and immunity.

To support the exploitation of the ubiquitin system Ubiquigent has recently launched the first novel compound library designed to target Deubiquitylase (DUB) enzymes (DUBtarget-001), with further compound libraries to follow. Ubiquigent also provides access to specialist drug discovery services, high quality research tools and chemistry to support groups that are either already active in or wish to enter this exciting new field.

The ubiquitin system is based on the modification of proteins through the attachment of the protein ubiquitin, or ubiquitin-like proteins (Ubls). Ubiquitylation and related Ubl modifications are key to the control of cellular protein homeostasis as well as signalling, akin to the critical role played by phosphorylation (approximately 30% of commercial drug discovery programmes target phosphorylation enzymes), and holds similar if not greater potential for clinical utility.

Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery. Ubiquigent benefits from high calibre backing including from IP Group plc, US investors, the UK Medical Research Council, and the University of Dundee. The company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.